HomeA2LC34 • BVMF
add
Alcon Inc
Previous close
R$49.89
Year range
R$35.88 - R$56.76
Market cap
38.32B CHF
Avg Volume
374.00
Market news
Financials
Income Statement
Revenue
Net income
(USD) | Sep 2024info | Y/Y change |
---|---|---|
Revenue | 2.45B | 5.37% |
Operating expense | 1.04B | -1.42% |
Net income | 263.00M | 28.92% |
Net profit margin | 10.72 | 22.37% |
Earnings per share | 0.81 | 22.73% |
EBITDA | 620.00M | 19.23% |
Effective tax rate | 9.93% | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Sep 2024info | Y/Y change |
---|---|---|
Cash and short-term investments | 1.99B | 88.78% |
Total assets | 30.36B | 3.38% |
Total liabilities | 8.97B | -2.65% |
Total equity | 21.39B | — |
Shares outstanding | 494.60M | — |
Price to book | 1.15 | — |
Return on assets | 2.76% | — |
Return on capital | 3.16% | — |
Cash Flow
Net change in cash
(USD) | Sep 2024info | Y/Y change |
---|---|---|
Net income | 263.00M | 28.92% |
Cash from operations | 747.00M | 41.75% |
Cash from investing | -483.00M | -217.76% |
Cash from financing | -81.00M | -910.00% |
Net change in cash | 194.00M | -50.26% |
Free cash flow | 661.88M | 69.93% |
About
Alcon Inc. is a Swiss-American pharmaceutical and medical device company specializing in eye care products. It has a paper headquarters in Geneva, Switzerland but its operational headquarters are in Fort Worth, Texas, United States, where it employs about 4,500 people.
Alcon was a subsidiary of Novartis until April 2019, when it was spun out into a separate publicly traded company. Alcon itself has a number of subsidiaries, including Aerie Pharmaceuticals, focused on therapies for glaucoma and other diseases of the eye, and WaveLight, which develops and manufactures laser eye surgery technologies. Wikipedia
Founded
1945
Headquarters
Website
Employees
25,000